Other studies demonstrated that loss of BCMA and GPRC5D is observed in 4% and 35% myeloma patients after treatment with BCMA CAR-T and GPRC5D CAR-T, respectively.146. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.